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Abstract Inherited mutations in BRCAl predispose to breast 
and ovarian cancer, but the biological function of the BRCAl 
protein has remained largely elusive. The recent correspondence 
of Koonin et al. [Koonin, E.V., Altschul, S.F. and Bork, P. 
(1996) Nature Genet. 13, 266-267] has emphasized the potential 
importance of the BRCAl C-terminal region for BRCAl-
mediated breast cancer suppression, as this domain shows 
similarities with the C-terminal regions of a p53-binding protein 
(53BP1), the yeast RAD9 protein involved in DNA repair, and 
two uncharacterized, hypothetical proteins (KIAA0170 and 
SPAC19G10.7). The highlighted domain has been suggested to 
be the result of an internal duplication, each of the tandem 
domains being designated as a 'BRCT domain' (for BRCAl C-
terminus). Sequence analysis using Hydrophobie cluster analysis 
reveals here the presence of 50 copies of the BRCT domain in 23 
different proteins, including, in addition to BRCAl, 53BP1 and 
RAD9, XRCC1, RAD4, Ect2, REVI, Crb2, RAPl, terminal 
deoxynucleotidyltransferases (TdT) and three eukaryotic DNA 
ligases. Most of these proteins are known to be involved in DNA 
repair. The BRCT domain is not limited to the C-termini of 
protein sequences and can be found in multiple copies or in a 
single copy as in RAPl and TdT, suggesting that it could well 
constitute an autonomous folding unit of approx. 90-100 amino 
acids. 
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1. Introduction 
The cloning of the familial breast and ovarian cancer sus-
ceptibility gene BRCAl [1] was an important milestone in 
cancer research. Cancer-predisposing alíeles of BRCAl, which 
generally behave as recessive alíeles in somatic cells, typically 
carry mutations that cause loss or reduction of the gene func-
tion and the wild-type alíele is lost in tumor tissue [1,2], sug-
gesting that BRCAl, like many other genes involved in famil-
ial cancer, is a tumor suppressor gene. In sporadic tumors, 
somatic point mutations are very rare; complete somatic dele-
tion of one alíele of BRCAl is often observed, with a decrease 
in BRCAl mRNA expression [3-6]. Evidence of a role in 
tumor suppression is further supported by the observations 
of growth acceleration of both normal and malignant breast 
epithelial cells following inhibition of BRCAl expression [7] 
and growth inhibition of tumor cell Unes after transfection 
with wild-type, but not mutant, BRCAl [8]. This activity ap-
»Corresponding author. Fax: (33) (1) 44 27 37 85. 
E-mail: callebau@lmcp.jussieu.fr 
Abbreviations: HCA, hydrophobic cluster analysis; TdT, terminal 
deoxynucleotidyltransferase. 
pears to be tumor-type specific as BRCAl cannot inhibit the 
growth of some other cancer cell lines, nor can it inhibit the 
growth of normal fibroblasts [8]. 
BRCAl encodes a predicted protein of 1863 amino acids 
containing in its NH2-terminus a single CsHQ-type zinc fin-
ger domain, also referred to as the RING finger or A-box and 
found in various proteins showing transactivation activity for 
a number of viral and cellular genes [1,9]. The rest of the 
protein was initially reported to contain no significant similar-
ities to any known genes. A recent report paradoxically sug-
gests that the BRCAl protein, whose sequence is found to 
match with a 'granin' consensus, might be secreted and so 
would function by a mechanism so far undescribed for tumor 
suppressor gene products [10]. On the other hand, several lines 
of evidence suggest that the C-terminal end of BRCAl is 
essential to the normal function of the protein in breast 
epithelial cells. Patients inheriting 1853Stop were shown to 
develop very early onset breast cancer [11]. Moreover, trunca-
tions of the BRCAl C-terminal region were shown to sup-
press the ability of BRCAl to inhibit breast cancer cell growth 
[8]. Finally, this region of BRCAl has recently been reported 
to act as a transcriptional transactivator when fused to the 
GAL4 DNA-binding domain [12]. 
In order to gain more insight into the structural and func-
tional features of this essential region, we have used hydro-
phobic cluster analysis (HCA) [13,14] in combination with 
well-established linear methods of sequence analysis. HCA is 
indeed able to detect three-dimensional similarities between 
proteins showing very limited sequence relatedness. Its sensi-
tivity at low levels of sequence identity (typically below the so-
called twilight zone (25-30%)) stems from its ability to detect 
significantly secondary structure elements [15]. The effective-
ness of the HCA method has been widely demonstrated (see, 
among others [16-20]). 
The use of this method has led us to identify within the 
BRCAl C-terminus a repeated motif which is widespread in 
several nuclear proteins closely related to cell cycle regulation 
and DNA repair. These findings complement the recent cor-
respondence of Koonin and colleagues [21] in which they re-
port the presence of this motif, which they named BRCT 
(BRCAl C-terminus), in the repair protein RAD9 and in a 
p53-binding protein. Here we extend the retrieval of this mod-
ule to XRCC1, RAD4, Ect2, REVI, Crb2, RAPl, terminal 
deoxynucleotidyltransferases (TdT) and three eukaryotic 
DNA ligases and emphasize its potential role in cell cycle 
control. 
2. Materials and methods 
Systematic searches of databanks [22,23] allow detection of se-
quences which could belong to the same functional and/or structural 
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family. However, at the low levels of sequence identity (< 25-30%) 
often observed, these automatic methods are unable to distinguish 
similarities due to structural relationships from background noise. 
The 'hydrophobic cluster analysis' method [13,14] is helpful in this 
regard insofar as it allows comparison of not only the sequences but 
also the protein secondary structures statistically centered on hydro-
phobic clusters, as well as their distribution [15]. Similar plots could 
therefore indicate similar three-dimensional folds. Guidelines to the 
use of this method are given in [13,14]. 
The HCA score is proportional to the hydrophobic amino acids 
which are topologically conserved (often not chemically identical), 
and therefore reflects the degree of conservation of the hydrophobic 
core. High HCA scores are associated with low root mean squares 
values between three-dimensional structures [14]. The accuracy of the 
alignments can be assessed by computing identity, similarity or HCA 
scores, as well as the corresponding Z scores as initially suggested by 
Doolittle [24]; these represent differences between the alignment score 
under consideration and the mean score of a distribution computed 
for alignment of sequence 1 versus a large number of randomly 
shuffled versions of sequence 2 (here 1000). These differences are ex-
pressed relative to the standard deviation (SD) of the random distri-
bution. Scores that are 3.0 or more standard deviation above the 
scrambled mean scores can reasonably be expected to represent 
authentic relationships. 
3. Results 
The BRCT family members listed in Fig. 1 have been iden-
tified by first searching the sequence databases using standard 
ID methods such as BlastP [23] and Fast A [22] and then 
sorting and assessing the putative 3D relationships to the 
family through HCA [13,14] (see Section 2). 
Conserved motifs (similar hydrophobic motifs often asso-
ciated with sequence conservation) define five regions, desig-
nated A-E, which can be used to decipher the main features 
of the BRCT module (Figs. 2 and 3). The most highly con-
served motif, motif D, is organized around a conserved aro-
matic residue (W, F or Y). The residue following it is always 
hydrophobic, as are usually the fourth and fifth residues pre-
ceding it. The conservation of this hydrophobic pattern can 
easily be visualized on the HCA plots (Fig. 3). Another strik-
ing feature of this motif D is that the fourth position after the 
conserved aromatic residue is usually occupied by a cysteine 
or a serine. Other positions also show some preferences for 
particular amino acids (often proline in positions —6 and —2 
and hydrophobic residues in position +5). The region corre-
sponding to this motif has been used by Koonin et al. [21] to 
derive a signature which, however, is too strict as it succeeds 
in 'picking up' only five proteins of the family. Moreover, in 
one of these five proteins, the SPAC19G10.7 hypothetical 
protein, the signature is not able to detect four additional 
BRCT domains which nonetheless harbor typical features of 
the module (Figs. 1 and 2). In particular, this pattern includes 
the region preceding the motif D which in fact appears less 
highly conserved than initially predicted. However, the use of 
a degenerate signature based on the unique motif D defined 
here is too permissive to describe BRCT domains. This motif 
should therefore be associated with several of the other motifs 
to assess the BRCT prediction. 
Motif B is the second most highly conserved feature of the 
domain: it consists of two consecutive glycines preceded in 
positions —4 and —8 (relative to the first glycine) by hydro-
phobic residues. Although this pattern is not absolutely con-
served in all of the domains, it can also be easily visualized on 
the plots as glycine is represented by a particular symbol 
(Fig. 3). 
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Fig. 1. Position of the BRCT domains within BRCT domain-con-
taining proteins. Abbreviations, correspondences and sequence refer-
ences are given in the legend to Fig. 2. Additional modules showing 
similarities with other proteins: RING, ring finger domain; POLß, 
region similar to polymerase ß; GEF, region similar to GTP-ex-
changing factor; UMUC, region similar to the bacterial DNA re-
pair protein UmuC; DBD, DNA binding domain; LIG, region 
showing similarities with human DNA ligase I and corresponding to 
the minimal size of ATP-dependent bacterial Hgases (Callebaut et 
al., in preparation); PARPz, region similar to the Zn fingers of hu-
man poly(ADP-ribose) polymerase (PARP). 
Motif C corresponds to a continuous stretch of three or 
four hydrophobic amino acids (a vertical shape in the HCA 
plots) or, in several domains, to the sequence ΤΗΦΦ where Φ 
is a hydrophobic amino acid (V, I or L). This motif most 
probably corresponds to an internal ß-strand. Two other ß-
strands probably constitute the motifs A and E, which begins 
and ends the domain, respectively, and whose shapes are also 
well retrieved within the family. 
The limits of the domain can be well defined, especially 
since in some proteins such as RAP1, it is surrounded by 
non-globular regions mainly composed of non-hydrophobic 
amino acids or is located N- or C-terminal in the protein 
sequences. Moreover, in RAP1 as well as in TdT, the 
BRCT domain is found isolated in a single copy, suggesting 
that it could well constitute an autonomous folding unit. The 
minimal length of this domain can be fixed to approx. 100 
amino acids but it appears to tolerate insertions of consider-
able length, especially between blocks A and B and blocks B 
and C (Fig. 2). 
In conclusion, this investigation within a family of proteins 
sharing very low levels of sequence identity enables the iden-
tification of BRCT domains only if several of the 'BRCT 
clues' are brought together in a compatible way, excluding 
isolated motifs, even the stronger ones, which can occur by 
chance. When the BRCT pattern was found to be highly 
divergent, we verified the proposition by carrying out ID 
searches with the candidate domain and retrieving in the out-
put compatible alignments with established members of the 
family. For example, the fifth BRCT domain of the hypothe-
tical protein F37D6.1 has a highly degenerate motif D (Figs. 2 
and 3), but the relationship with the BRCT family is sup-
ported by the fact that it can be aligned with reasonable 
scores to SPAC19G10.7 and RAD4 (BLASP P values = 0.041 
and 0.058 with the BLOSUM62 matrix, respectively). Good 
similarities also appear with BRCA1. In this example, the 
similarities are especially concentrated in the region of motifs 
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Fig. 2. HCA-based alignment of BRCT domains. The position of the first amino acid is given for each domain. Five aligned blocks (designated 
A-E) constituting the five conserved regions of the domain are separated from each other by more variable regions. Distances between the 
blocks are indicated by numbers within parentheses. Star indicates the end of a sequence. Highly conserved motifs are shown boxed. Alterna-
tive solutions to the proposed alignment of Koonin et al. [21] are given for the BRCAl I and RAD9 I blocks A, as well as for the 
SPAC19G10.07-1 block A (reported with a write error in [21]). The second BRCT domain of the C. elegans F37D6.1 hypothetical protein is 
shown separately as it possesses a highly divergent block D. Sequences were taken from the SWISS-PROT (sw), PIR (pir) and Genbank (gb) 
databases and are listed here with their accession numbers (AC): (A) hBRCAl = human BRCAl (sw AC: P38398, 1863 amino acids), 
h53BPl=human 53BP1 (gb AC: U09477, 1027 amino acids), hXRCCl =human XRCC1 (sw AC: P18887, 633 amino acids), hTDT = human 
terminal deoxynucleotidyltransferase (sw AC: P04053, 508 amino acids), mECT2 = mouse Ect2 oncogene (pir AC: S32372, 738 amino acids), 
scRAD9 = 5. cerevisiae RAD9 (sw AC: P14737, 1309 amino acids), scREVl = S'. cerevisiae REVI (sw AC: P12689, 985 amino acids), 
scRAPl = 5. cerevisiae RAP1 (sw AC: PI 1938, 827 amino acids), klRAPl=Ä: lactis RAP1 (gb AC: X73629, 666 amino acids), spCRB2 = 5. 
pombe Crb2 (gb AC: D86478, 778 amino acids), spRAD4 = S.pombe RAD4 (sw AC: P32372, 648 amino acids), hDNL3 = human DNA ligase 
III (gb AC: X84740, 922 amino acids), hDNL4 = human DNA ligase IV (gb AC: X84441, 844 amino acids), caDNLI= C. albicans DNA ligase 
(gb AC: X95001, 864 amino acids). (B) Uncharacterized proteins from human (h), S. cerevisiae (sc), S.pombe (sp) and C. elegans (ce): 
MOAA0170 (gb AC: D79992, 2088 amino acids), scYOR005c (gb AC: Z74913, 944 amino acids), scYM8021.03 (pir AC: S54584, 732 amino 
acids), scYGR103w (gb AC: Z72888, 605 amino acids), scYHV4 (sw AC: P38850, 1070 amino acids), scYJJO (sw AC: P47027, 764 amino 
acids), spSPAC19G10.07 (gb AC: Z69909, 878 amino acids), ceF37D6.1 (gb AC: Z75540, 1214 amino acids), ceZK675.2 (gb AC: Z46812, 
1027 amino acids), ceT19E10.1 (gb AC: Z46795, 932 amino acids). The sequence of the S. cerevisiae hypothetical protein UNE452 (gb AC: 
U43491, 452 amino acids) is identical to that of scYOR005c. The sequence of the S. cerevisiae hypothetical protein YJJO is identical to that of 
Dpbll, which interacts with DNA polymerase II (epsilon) and has a dual role in S-phase progression and a cell cycle checkpoint [54]. The se-
quences of the BRCT domains of mouse, bovine, chicken and X. laevis TdTs are not shown as they share more than 50% identity with the 
BRCT domains of human TdT (85, 86, 63 and 59%, respectively). The sequences of the two BRCT domains of mouse BRCAl, sharing 75 and 
58% identity with those of human BRCAl, respectively, are also not shown. 
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Fig. 3. Comparison of the HCA plots of BRCT domains of human 
BRCA1 (the two domains), human 53BP1 (first one), S. cerevisiae 
RAP1 and C. elegans F37D6.1 (fifth one). Conserved regions (A-E) 
described in Fig. 2 are shown within boxes. The protein sequences 
are written on a duplicated a-helical net and the contours of clus-
ters of hydrophobic residues are automatically drawn. The standard 
one-letter code for amino acids is used except for proline (regular 
secondary structure breaker), glycine (the least constrained amino 
acid), serine and threonine (which can be accommodated either at 
the protein surface or in a hydrophobic environment masking their 
hydroxyl group through an H-bond with the polypeptide backbone) 
which are represented by (*), (♦) , (B) and (D), respectively. 
B (the two glycines are present) and C (containing the se-
quence ΤΗΦΦ which is frequently retrieved and where Φ is 
an hydrophobic amino acid). Paradoxically, the use of this 
non-typical BRCT domain has allowed detection of the 
unique BRCT domain of the terminal deoxynucleotidyltrans-
ferase (TdT), which otherwise possesses a typical motif D. 
However, the presence of the motif was pointed out only 
through HCA, as the BlastP alignment (with a P value of 
1.0) focused only on the B and C motifs. 
As a general rule, pairwise identity and similarity scores 
leave little doubt about the relationships between the different 
domains described here. They were further assessed by the 
calculation of the 1225 pairwise Z scores (number of standard 
deviations that the score of pairwise optimally aligned se-
quences differs from the 'random' mean). The mean and 
standard deviation of identity Z scores are 3.03 and 1.80, 
respectively; those of similarity Z scores (using the Dayhoff 
matrix [25]) are 3.90 and 1.67, respectively (4.21 and 1.82 
when using the BLOSUM62 matrix [26]). 
Finally, profile searches with the multiple alignment given 
in Fig. 2 resulted in higher scores for the above-mentioned 
BRCT domains than for all other proteins of the sequence 
databases. 
The BRCT domain was initially highlighted as a tandem 
duplicate in the C-terminal regions of BRCA1, the p53-bind-
ing protein 53BP1, and the RAD9 protein involved in DNA 
repair [21]. We show here that the BRCT domain can be 
retrieved widespread and arranged in different ways in the 
proteins shown in Fig. 1. Saka et al. [27] have already pointed 
out the presence of the two tandem repeats in RAD4 and 
have related them to similar regions found in the oncogene 
Ect2 [28] (two domains) and the repair proteins REVI [29] 
(one domain) and XRCC1 [30] (one domain). However, they 
were not able to detect the second BRCT domain of XRCC1 
which is separated from the first by an acidic region. This 
domain nonetheless possesses strong features of the family 
(Fig. 2). Nor was any relationship detected with the rest of 
the family, which includes terminal deoxynucleotidyltrans-
ferases (TdT), RAP1, three eukaryotic DNA ligases and 
Crb2 and several hypothetical proteins (Fig. 1). 
4. Discussion 
The discovery of a common domain between BRCA1 and a 
p53-binding protein has led to the hypothesis that BRCA1 
may bind p53, the universal tumor suppressor [21]. The re-
trieval of this domain, named BRCT (for BRCA1 C-Termi-
nus), in the yeast RAD9 protein [21] also indicates that 
BRCA1 may play a role in cell cycle checkpoints, the negative 
controls which impose delays in the eukaryotic cell cycle [31]. 
Following DNA damage, RAD9 is required to delay the cell 
cycle at the Gl and G2 checkpoints [32,33]. RAD9 is also 
involved in another signal related to DNA repair as it partic-
ipates in the transcriptional response to DNA damage by 
controlling the induction of a large 'regulon' of repair, repli-
cation and recombination genes [34]. In this context, it is 
interesting to note that truncations of the BRCA1 C-terminal 
region, encompassing the BRCT domains, were shown to sup-
press the ability of BRCA1 to inhibit breast cancer cell 
growth, suggesting that it negatively regulates cell division 
[8]. Moreover, this region of BRCA1 has recently been re-
ported to act as a transcriptional transactivator when fused 
to the GAL4 DNA-binding domain [12]. The investigation of 
the target genes regulated by BRCA1 would certainly enhance 
our understanding of the potential role of BRCA1 in cell cycle 
control and repair/replication-associated processes. Given the 
fact that p53 is known to trigger cell cycle delay at Gl [35,36], 
it is plausible to hypothesize that the potential activity of 
BRCA1 in cell cycle regulation occurs through an interaction 
with p53. 
The hypothesis of a role of BRCT domains in cell cycle 
DNA 
ligases 
-j , , "T human I 
DNA 
poiymerase 
family X 
-Γ 
T _ A human HI 
> Q - Q human 
T — A - C.aMca 
0 BRCT module 
Fig. 4. Enzymes containing BRCT domains - relationship to related 
proteins. The BRCT domains are shown grey shaded. The structures 
of the enzymatic domains of the DNA ligase of bacteriophage T7 
(bpt7) and rat polymerase ß (polß), represented by hatched boxes, 
have been solved experimentally ([55] and [47,48], respectively). 
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regulation and in repair mechanisms is strengthened here by 
the observation that this module is found to be widespread in 
other proteins also closely involved in these processes. Human 
XRCC1, which was shown here to possess two copies of the 
BRCT module, is required for repair of DNA single-strand 
breaks formed by exposure to ionizing radiation and alleviat-
ing agents [30]. The S. cerevisiae REVI gene product func-
tions in a cellular process required for mutagenesis caused by 
UV radiation and many chemical mutagens [29]. Mutations in 
S. pombe RAD4 are known to confer sensitivity to UV and 
ionizing radiation damage, as well as a temperature-sensitive 
phenotype [37,38]. For some of these proteins like for 
BRCA1, several lines of experimental evidence suggest a di-
rect functional role of the BRCT module in cell cycle control. 
Indeed, the N-terminal domain of RAD4 (cutS), containing 
the first tandem repeat, is essential for complementation of 
temperature-sensitive cut5 mutants [39] and its overexpression 
severely inhibits cell division [27]. Truncation of the N-ter-
minal domain of the oncogene product Ect2 encompassing 
its two BRCT domains increases its transforming activity, 
suggesting that this region has a negative effect on cell division 
[28]. 
Three of the proteins reported here as members of the 
BRCT family are known to possess a catalytic activity. Ter-
minal deoxynucleotidyltransferase (EC 2.7.7.31; TdT) is a 
template-independent DNA polymerase which catalyzes the 
elongation of polydeoxynucleotide chains by terminal addi-
tion [40]. One of the in vivo functions of this enzyme is the 
addition of nucleotides at the junction of rearranged Ig heavy 
chain and T cell receptor gene segments during the maturation 
of B and T cells [41-44]. It belongs to the family X of DNA 
polymerases which contains vertebrate polymerases ß [45]. 
Both enzymes, TdT and polymerase ß, share similarities with-
in the catalytic domain [46-48] although TdT has an addi-
tional N-terminal domain reported to be non-essential but 
shown here to correspond to a BRCT domain (Fig. 4). The 
primary difference between the two enzymes is the utilization 
of template by polymerases ß and not by TdT, but the reason 
for this difference is thought to he in the divergence of the 
template binding domain included in the catalytic domain, 
rather than in the presence of an additional domain in TdTs 
[46]. 
Interestingly, the yeast REVI protein, which also possesses 
a single copy of the BRCT module, has recently been reported 
to have a deoxycytidyl transferase activity which transfers a 
dCMP residue from dCTP to the 3' end of a DNA primer in a 
template-dependent reaction [49]. As it uses only dCTP, at 
least with the template primers tested, and in view of its un-
usual template requirements, REVI would represent a new 
category of nucleotide polymerizing enzymes. The presence 
of a common BRCT motif between two of these enzymes, 
TdT and REVI, is suggestive of a functional role in the poly-
merization event although it is apparently not directly linked 
to the enzymatic activity, as suggested by its non-essential role 
in TdT and its absence in polymerase ß. 
The BRCT domains found in three eukaryotic, ATP-de-
pendent DNA ligases are also located outside the predicted 
catalytic domain of these enzymes. ATP-dependent ligases 
(EC 6.5.1.1) are found in eukaryotes, archaebacteria, viruses 
and phages whereas bacterial DNA ligases are NAD-depend-
ent (EC 6.5.1.2). Four DNA ligases, I-IV, have been identified 
in mammalian cells. A short peptide sequence conserved close 
29 
to the C-terminus of all known eukaryotic DNA ligases has 
allowed the identification of DNA ligases III and IV [50]. 
Compared to DNA ligase I, DNA ligases III and IV possess 
additional domains following a conserved catalytic domain 
which are shown here to correspond to BRCT domains (one 
and two domains for DNA ligase III and IV, respectively Fig. 
4). A similar organization is found in the DNA ligase of C. 
albicans, with a single copy of the BRCT module following 
the catalytic domain (Fig. 4). Interestingly, DNA ligase III is 
known to form a characteristic, high-salt-resistant complex 
with XRCC1 [50]. 
A single BRCT module can also be retrieved in the yeast 
RAPl, a multifunctional protein which in addition to its role 
in regulating telomere length and initiating telomeric silencing, 
functions as a context-dependent transcriptional regulator at 
many other sites throughout the genome [51]. It contains a 
centrally located DNA-binding domain, a C-terminal domain 
including regulatory domains for both activation and repres-
sion of transcription and an N-terminal part which has no 
known biological function, except for its involvement in in 
vitro DNA bending [52]. It is this very region which is 
made of non-globular regions surrounding a single BRCT 
domain. 
The non-essential character of the BRCT domain of RAPl 
and enzymes such as TdT apparently contrasts with the fact 
that it is retrieved widespread within proteins which are re-
lated by their close involvement in DNA metabolism and with 
the important role that it may play in cell cycle control in 
RAD4, ECT2 and BRCA1. Given these data, it is tempting 
to speculate about the molecular role of BRCT domains. This 
module might serve to interact with other proteins involved in 
cell cycle regulation, as suggested by the fact that it is present 
in a p53-binding protein and that the human DNA ligase III 
tightly binds XRCC1 [50]. However, no experimental evidence 
exists for a direct involvement of the BRCT domains, rather 
than other domains contained in these large proteins, in pro-
tein-protein interaction. Another hypothesis is that the BRCT 
module might be a molecular sensor allowing direct or indi-
rect recognition of particular DNA structures. This recogni-
tion could allow the activation of repair mechanisms or, on 
the contrary, protect the recognized region from the repair 
system. In this context, it is interesting to note that, in addi-
tion to its known binding activity for double-stranded DNA, 
RAPl binds sequence in a sequence specific manner to the 
telomeric terminal GT tails [53]. However, this novel DNA 
binding activity involves regions of RAPl located outside of 
the DNA binding domain. Whether or not it involves the 
BRCT domain therefore deserves some further investigation. 
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